Smurfit Kappa Group Work in process increased by 6.8% to $205.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.4%, from $210.00M to $205.00M. Over 2 years (FY 2023 to FY 2025), Work in process shows an upward trend with a 92.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $52.00M | $240.00M | $206.00M | $210.00M | $222.00M | $208.00M | $192.00M | $205.00M |
| QoQ Change | — | +361.5% | -14.2% | +1.9% | +5.7% | -6.3% | -7.7% | +6.8% |
| YoY Change | — | — | +296.2% | — | — | -13.3% | -6.8% | -2.4% |
| % of Inventories | 4.3% | 6.7% | 5.8% | 5.7% | 5.9% | 5.5% | 5.2% | 5.7% |
| Share Change | — | +2.4pp | -0.9pp | -0.1pp | +0.2pp | -0.4pp | -0.3pp | +0.5pp |